This study reports on overall and recurrence-free survival (OS and RFS) of 37 consecutive patients with low-and intermediate-grade NHL receiving a related donor allogeneic BMT using a nonradiation-containing preparative regimen. In addition, transplant-related toxicity and factors influencing outcome are discussed. The preparative regimen consisted of busulfan and cyclophosphamide. Median patient age was 44 years (range 20-55). In all, 18 were female. Median follow-up of surviving patients from BMT was 4.2 years. A total of 25 patients had low-grade, and 12 intermediate grade NHL. Most patients (89%) were treated with at least two different chemotherapy regimens prior to BMT. In all, 22 patients (59%) were transplanted in partial remission, 15 (41%) in complete remission. OS at 12 months was 89% (95% confidence interval (CI) of 79-99%) and 79% (64-93%) at 60 months. RFS at 12 months was 86% (75-97%) and at 5 years 70% (54-86%). Four patients (11%) relapsed. Seven patients (19%) died, six because of treatmentrelated toxicity and one with relapse. Univariate analysis showed improved OS for younger patients and patients of female gender, suggesting that allogeneic BMT using busulfan-cyclophosphamide as a preparative regimen can achieve disease control and possibly cure patients with NHL particularly younger ones.
transplantation; busulfan; cyclophosphamide; graft-versus-lymphoma effect Autologous blood and marrow transplantation (ABMT) is considered the treatment of choice for a number of patients with relapsed non-Hodgkin's lymphoma (NHL). 1 Limitations of this therapy include a significant relapse rate particularly in patients with low-grade lymphoma. 2, 3 In addition, ABMT is thought to be less beneficial in patients with bone marrow involvement or significant residual disease at the time of transplant. 4 In a number of patients, the inability to collect a sufficient number of hemopoietic progenitor cells precludes autologous transplantation. These issues have led to studies with alternative treatment approaches in patients with NHL including allogeneic bone marrow transplant (BMT). 5 This treatment modality has been used in a growing number of patients. [6] [7] [8] Reports have demonstrated feasibility and suggested the presence of a graft-versus-lymphoma effect. 9, 10 Medical outcomes of patients with low-grade lymphoma reported to the International Bone Marrow Transplant Registry on allogeneic related sibling transplantation have been reported recently. 7 In all, 113 patients were transplanted, 80% with stage IV disease at the time of transplant. The conditioning regimen included radiation in 82% of cases. The median follow-up of surviving patients was 25 months with a probability of 3-year disease-free survival (DFS) of 49%. A retrospective comparison between allogeneic and autologous transplantation for patients with low-grade NHL has been reported 8 and updated. 11 In all, 33 patients were reported in the updated publication. Of these, 18 received an autologous and 15 a related allogeneic donor transplant. All patients were prepared with a radiation-containing regimen. Four allograft recipients died from treatment-related complications as compared to no patient in the autologous transplant group. Event-free survival at 3 years was statistically significantly superior among the allogeneic transplant group (70 vs 22%, P ¼ 0.015). 11 In the province of Ontario since 1986 the strategy has been to perform autologous transplants in patients with relapsed NHL. In cases of persistent marrow involvement or inadequate stem cell harvest, allogeneic transplant was done using a number of different preparative regimens if there was a matched related donor. 12 All patients transplanted in this province between 1986 and 1997 were included in the final analysis. In all, 385 patients received an autologous and 44 an allogeneic transplant. Three-year actuarial survival was not statistically significantly different between the autologous and allogeneic groups (62 vs 71%, P ¼ 0.5). However, the relapse rate was lower after allogeneic transplantation (41 vs 6%, P ¼ 0.0006). 12 At Princess Margaret Hospital allogeneic transplantation was first offered to patients with NHL, who were not eligible for an autologous transplant because of residual marrow involvement or failure to mobilize a graft. A nonradiation containing regimen with busulfan-cyclophosphamide (bu-cy) was chosen because of reports of efficacy 13 and acceptable toxicity profiles 14, 15 in high-risk patients with hemopoietic malignancies and to allow uniform treatment of all patients, including those who had been exposed to dose-limiting radiation prior to transplant. 16 The purpose of this review was to report the medical outcomes of 37 consecutive patients with low-and intermediate-grade NHL receiving a related donor allogeneic BMT using bu-cy as the preparative regimen and to discuss the therapeutic impact as well as toxicity of this regimen. Results of a univariate analysis to identify factors influencing outcome are presented.
Patients and methods

Study design and patients
A retrospective analysis of patients charts and the BMT computer database was conducted. In all, 37 consecutive patients with low-or intermediate-grade NHL who received a matched related allogeneic bone marrow or peripheral stem cell transplant at Princess Margaret Hospital with bu-cy as the preparative regimen between 1 January 1989 and 30 June 1999 were included in this study. Patients with a related donor were offered allogeneic BMT if they were not eligible for autologous transplantation based on bone marrow involvement 12 or based on physician and patient preference.
BMT procedure
The preparative regimen consisted of oral busulfan at 4 mg/ kg p.o. divided in four daily doses for 4 days (total dose of 16 mg/kg), followed by cyclophosphamide 60 mg/kg once daily i.v. for 2 days (total dose of 120 mg/kg). Phenytoin was administered during the preparative regimen to prevent busulfan-associated seizures.
Standard cyclosporine and methotrexate 17 were used for graft-versus-host disease (GVHD) prophylaxis. Patients undergoing syngeneic transplantation received an abbreviated course of cyclosporine in an attempt to induce a graft-versus-lymphoma effect. 18 Patients were transplanted in isolation rooms. Antiviral prophylaxis included acyclovir 200-400 mg p.o. BID or an equivalent IV dose from days 1 to 28. Trimethoprim/sulfamethoxazole two tablets p.o. BID or an equivalent IV dose was used starting from the day of hospital admission until recovery of neutrophil counts. Trimethoprim/sulfamethoxazole was used after day 28 for Pneumocystis carinii prophylaxis for 1 year following transplant or longer if patients remained on immunesuppressive medications. Patients with allergies to trimethoprim/sulfamethoxazole or patients with significant bone marrow suppression received aerosolized pentamidine at a dose of 300 mg every 2-4 weeks.
Red cell depletion of the donor bone marrow was performed in ABO incompatible donor-recipient pairs. None of the grafts was T cell depleted.
Pre-emptive screening for cytomegalovirus (CMV) was done since 1992 using day 35 bronchoscopy or serial CMV serum antigenemia testing when either donor or recipient was serologically CMV positive prior to transplant and IV ganciclovir administered when positive.
Statistical methods
The principal end points in this study included overall and recurrence-free survival (OS and RFS) measured from the date of transplant. For OS an event was defined as death because of any cause. The survival times of patients who were alive at the last follow-up were censored. For RFS events included either disease recurrence or death without disease. The relapse-free survival times of patients were censored if they were alive and relapse free at the last follow-up. OS and RFS curves were produced using the method of Kaplan and Meier. 19 The 95% CI for OS and RFS proportions were based on the normal approximation to the binomial distribution. One-and 5-year rates for OS and RFS were chosen considering these as standard rates. As the median follow-up of patients was 4.2 years, we thought it better to quote 3-year results in the univariate analysis as compared to 5-year results.
A univariate prognostic factor analysis was performed for both OS and RFS looking at baseline pretransplant parameters. Candidate prognostic variables included age in years (p44 vs 444), patient gender (males vs females), remission status (partial remission (PR) vs complete remission (CR)), grade (low versus intermediate), previous bulky disease (no vs yes), B symptoms (no vs yes), previous radiation therapy (no vs yes) and number of previous chemotherapy regimens (p2 vs 42). As each variable was defined on a categorical scale the log rank test 20 was used to compare OS and RFS among each category. Given no a priori cutoff for age the median value was chosen in order to maximize the sample size in each subgroup. Owing to the relatively small number of events a multivariate analysis was not attempted.
The proportion of female donors among female patients was compared to the proportion of male donors among male patients using Fisher's exact test.
All reported P-values were two-sided. All analyses were performed with SAS Version 8.
CR was defined as no evidence of lymphoma on standard evaluation. PR was defined as a significant response to treatment with at least 50% reduction of average tumor size. Veno-occlusive disease (VOD) of the liver, acute and chronic GVHD were defined as per previously published criteria. [21] [22] [23] Neutrophil engraftment was defined by the first of two consecutive days of a neutrophil count of greater than 0.5 Â 10 9 /l. Platelet engraftment was defined as the first of 6 days of a sustained platelet count of 420 Â 10 9 /l. In 33 patients, bone marrow was used as the source of stem cells while four patients received a peripheral blood stem cell transplant.
Survival and relapse
Medical outcomes are summarized in Table 2 . Of 37 patients, seven have died. OS at 1 year was 89% (CI 79-99%) and at 5 years 79% (64-93%). Recurrence or persistent disease was noted in four patients. RFS at 1 year was 86% (75-97%) and at 5 years 70% (54-86%). Survival curves depicting OS and RFS using Kaplan Meier plots are shown in Figures 1 and 2 , respectively.
Four syngeneic twin transplant recipients were included in this study. All of them were alive with no relapses noted at study closure with a median follow up of 5.4 years (range 4-9).
Toxicity
Acute GVHD (grade 2-4) was noted in 24 (65%) of patients. Chronic GVHD occurred in 20 (54%). In all, 13 /l at a mean of 48.4 days.
Seven patients died, three with pneumonia (two fungal, one Pneumocystis carinii), one each with acute GVHD, bronchiolitis obliterans, interstitial pneumonitis and disease relapse.
Prognostic factor analysis
A univariate analysis was performed to identify factors prognostic for survival and RFS. Gender was statistically significantly related to OS and RFS (P ¼ 0.004 and 0.003, respectively) with females demonstrating more favorable outcomes than males (Figure 3) . The survival advantage among female patients persisted when only patients who had a fully HLA-matched sibling donor were analyzed (N ¼ 27, OS P ¼ 0.019, RFS P ¼ 0.038). Younger patients, below the median age of the group of 44 years, had significantly better OS (P ¼ 0.03) (Figure 4) . Remission status at BMT was not a statistically significant predictor of outcome. None of the other candidate prognostic factors was found to be statistically significant. These included grade at diagnosis (low-vs intermediate-grade lymphoma), previous bulky disease, previous B symptoms, previous radiation or number of previous chemotherapy regimens (Table 3) .
Discussion
Allogeneic BMTs are being used more frequently as a treatment modality for patients with NHL with multiple different preparative regimens. In this study, we report outcomes of consecutive patients with NHL receiving an allogeneic BMT in a single institution using the combination of (bu-cy) as the preparative regimen. This regimen was chosen to allow inclusion of patients with previous radiation therapy. In patients with NHL this preparative regimen has been described in the setting of autologous transplantation 24, 25 and less commonly for allogeneic transplants. 26 Patients were offered allogeneic BMT in our study if they were not deemed eligible for an autologous transplant mainly based on bone marrow involvement with disease.
The OS and RFS in our group of patients at 5 years amounted to 79 and 70%, respectively. Treatment-related Bu-cy and allogeneic BMT in patients with NHL T L Kiss et al mortality, toxicity and relapse rate were relatively low considering that most patients had advanced disease and were heavily pretreated with multiple courses of chemotherapy. All patients achieved a complete remission post-transplant except for one patient with low-grade lymphoma, who showed evidence of relapse or persistent disease very shortly after transplant. This patient consecutively achieved CR following withdrawal of immune suppression and treatment with interleukin 2.
No excessive toxicity was noted in our group of patients. Graft failure was noted in only one patient (3%). Acute (4grade 1) and chronic GVHD were noted in 65 and 54% of patients, respectively. VOD was noted in 27% of patients but did not cause death in any patient.
Results presented in this study appear similar or superior to those of previously published reports by Verdonck et al 11 (N ¼ 15, OS of 70%) or van Besien 9 (N ¼ 113, OS of 49%), However, direct comparisons remain difficult because of the differences in patient populations described. Most patients in these reports received a TBI containing preparative regimen with heterogeneous GVHD prophylaxis in contrast to our study. Reports of bu-cy as the preparative regimen for treatment of patients with NHL in the setting of autologous transplantation 24, 25 have included patients with low-and intermediate-grade lymphoma. OS ranged between 50 and 58%. The proportion of patients surviving at 2 years as reported by Avalos et al, 26 receiving an allogeneic BMT with bu-cy was 55% (N ¼ 11), However, patients with high-grade lymphomas were also included in this report.
Univariate analysis was performed to identify factors predictive of outcome. There was no difference in either survival or RFS when patients with low-vs intermediategrade lymphoma were compared. Patients with partial remission, more than two chemotherapy regimens prior to transplant, previous radiotherapy and bulky disease at the time of diagnosis had a trend towards worse outcomes in terms of OS and RFS (curves not shown). These results were not significant, perhaps relating to the small patient numbers leading to underpowering of the study. Significantly different, however, was the gender-related outcome of patients, with female patients showing improved OS and RFS. The reason for better outcome in female patients is unclear. Inferior outcomes for male patients following allogeneic BMT have been previously described in the setting of patients receiving allogeneic transplantation for myelodysplastic syndrome. Male patients showed increased nonrelapse mortality (P ¼ 0.007). 27 A significant difference for OS was also noted when comparing patients 44 years or younger (equivalent to median age of group) with the older age group. This is in keeping with published reports. 7 It is of note that none of the four recipients of syngeneic grafts have relapsed in spite of a relatively mature follow-up time.
More recently, IV bu has been used as a component of preparative regimens in allogeneic transplantation with encouraging results. 28 Further studies are required to demonstrate whether improvement of outcomes may be achieved by using an IV bu formulation in patients receiving an allogeneic transplant for NHL particularly as it has been discussed whether busulfan may contribute to an elevated risk for VOD. 29 In conclusion, the majority of patients with NHL receiving an allogeneic BMT with a nonradiation-containing preparative regimen using bu-cy have favorable outcomes, with acceptable toxicity particularly in the younger age group. Further studies using allogeneic BMT with this preparative regimen in patients with NHL are warranted.
